Volker Heinemann

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. doi request reprint Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action
    V Heinemann
    Comprehensive Cancer Center der LMU Krebszentrum München, Munchen, Germany
    Cancer Treat Rev 39:592-601. 2013
  2. pmc Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
    V Heinemann
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Br J Cancer 108:766-70. 2013
  3. doi request reprint Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
    Volker Heinemann
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Gut 62:751-9. 2013
  4. ncbi request reprint Treatment of locoregional disease: adjuvant versus neoadjuvant
    V Heinemann
    Department of Medical Oncology and Comprehensive Cancer Center, Ludwig Maximilian University of Munich, Munich, Germany
    Ann Oncol 23:x141-7. 2012
  5. doi request reprint Systemic treatment of advanced pancreatic cancer
    Volker Heinemann
    Klinikum Grosshadern, Department of Oncology and Comprehensive Cancer Center, Ludwig Maximilians Universitat Munchen, Germany
    Cancer Treat Rev 38:843-53. 2012
  6. pmc LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
    Carl Christoph Schimanski
    First Deptartment of Internal Medicine, University Medical Center UMC, University Hospital of Mainz, Mainz, Germany
    BMC Cancer 12:144. 2012
  7. pmc Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 8:82. 2008
  8. doi request reprint Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer
    Volker Heinemann
    Department of Medical Oncology, University of Munich, Campus Grosshadern, Munich, Germany
    Oncology 79:118-28. 2010
  9. ncbi request reprint Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
    Volker Heinemann
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern, Munich, Germany
    J Clin Oncol 24:3946-52. 2006
  10. doi request reprint A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
    V Heinemann
    Medical Department III, University of Munich, Munich, Germany
    Ann Oncol 22:603-8. 2011

Detail Information

Publications127 found, 100 shown here

  1. doi request reprint Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action
    V Heinemann
    Comprehensive Cancer Center der LMU Krebszentrum München, Munchen, Germany
    Cancer Treat Rev 39:592-601. 2013
    ..In this review we will discuss the discovery and ongoing investigation into predictive biomarkers for mCRC as well as how recent advances have impacted on clinical practice and ultimately the overall cost of treatment for these patients...
  2. pmc Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer
    V Heinemann
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Br J Cancer 108:766-70. 2013
    ..Conclusion:In this proof-of-concept study targeting the uPA system in LAPC, the addition of upamostat to gemcitabine was tolerated well; similar survival results were observed for the three treatment arms...
  3. doi request reprint Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft Internistische Onkologie' (AIO-PK0104)
    Volker Heinemann
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Gut 62:751-9. 2013
    ....
  4. ncbi request reprint Treatment of locoregional disease: adjuvant versus neoadjuvant
    V Heinemann
    Department of Medical Oncology and Comprehensive Cancer Center, Ludwig Maximilian University of Munich, Munich, Germany
    Ann Oncol 23:x141-7. 2012
    ..New avenues of individualized treatment may also be reached by the inclusion of molecular parameters of the tumor and pharmacogenomic profiles of the patient into decision making...
  5. doi request reprint Systemic treatment of advanced pancreatic cancer
    Volker Heinemann
    Klinikum Grosshadern, Department of Oncology and Comprehensive Cancer Center, Ludwig Maximilians Universitat Munchen, Germany
    Cancer Treat Rev 38:843-53. 2012
    ....
  6. pmc LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial
    Carl Christoph Schimanski
    First Deptartment of Internal Medicine, University Medical Center UMC, University Hospital of Mainz, Mainz, Germany
    BMC Cancer 12:144. 2012
    ..In a phase IIB trial, L-BLP25 has shown acceptable tolerability and a trend towards longer survival in patients with stage IIIB locoregional NSCLC...
  7. pmc Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
    Volker Heinemann
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 8:82. 2008
    ..Single-agent gemcitabine (GEM) is a standard treatment for advanced and metastatic pancreatic cancer. This study examines the question whether GEM-based combination chemotherapy can further improve treatment efficacy...
  8. doi request reprint Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer
    Volker Heinemann
    Department of Medical Oncology, University of Munich, Campus Grosshadern, Munich, Germany
    Oncology 79:118-28. 2010
    ..This review describes the evolution of irinotecan-based regimens for metastatic colorectal cancer and evaluates the addition of bevacizumab to these regimens...
  9. ncbi request reprint Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer
    Volker Heinemann
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern, Munich, Germany
    J Clin Oncol 24:3946-52. 2006
    ..To compare the effectiveness and tolerability of gemcitabine plus cisplatin with single-agent gemcitabine as first-line chemotherapy for locally advanced or metastatic pancreatic cancer...
  10. doi request reprint A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer
    V Heinemann
    Medical Department III, University of Munich, Munich, Germany
    Ann Oncol 22:603-8. 2011
    ..v. vinorelbine plus trastuzumab as first-line regimen in a patient-convenient application for human epidermal growth factor receptor 2 (HER2)-overexpressing patients with metastatic breast cancer...
  11. doi request reprint [Medical-oncological aspects in the treatment of pancreatic cancer]
    V Heinemann
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen, Marchioninistr 15, 81377, Munchen, Deutschland
    Radiologe 49:144-8. 2009
    ..Patients in a good general condition but where the gemcitabine-based therapy failed should be offered second-line treatment...
  12. ncbi request reprint Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study
    V Heinemann
    Medical Clinic III, Klinikum Grosshadern, Munich, Germany
    Ann Oncol 18:1652-9. 2007
    ..The aim was to evaluate the efficacy of gemcitabine combined with a platinum agent compared to single-agent gemcitabine in a pooled analysis of two randomized trials...
  13. doi request reprint [Multimodality treatment concepts for metastatic breast cancer]
    V Heinemann
    Medizinische Klinik und Poliklinik III, Comprehensive Cancer Center LMU, Klinikum der Universitat Munchen, Marchioninistrase 15, 81377, Munchen
    Internist (Berl) 51:1358-65. 2010
    ..While large prospective trials are missing to support the beneficial effect of this strategy, retrospective analyses are highly suggestive offering rapid disease control and even long-term survival in selected patients...
  14. ncbi request reprint [Neoadjuvant and adjuvant therapies for solid tumours]
    Volker Heinemann
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern LMU München
    MMW Fortschr Med 149:27-30. 2007
    ..In ongoing clinical studies, the possibilities of influencing the effect of epidermal growth factor (EGF) as well as vascular endothelial growth factor (VEGF) are being investigated...
  15. doi request reprint Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer
    Michael Haas
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377 Munich, Germany
    Tumour Biol 31:351-7. 2010
    ..86, p = 0.001) and CRP (HR 3.20, p = 0.001). Serum biomarker kinetics might serve as useful prognostic tools during second-line chemotherapy in advanced pancreatic cancer...
  16. doi request reprint Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer
    Stefan Boeck
    Department ofInternal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 73:221-7. 2007
    ..Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients...
  17. doi request reprint Prospective multicenter randomized phase III study of weekly versus standard docetaxel plus doxorubicin (D4) for first-line treatment of metastatic breast cancer
    Hans Joachim Stemmler
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
    Oncology 79:204-10. 2010
    ..The present trial was initiated to compare the toxicity and efficacy of weekly docetaxel versus its standard 3-weekly application in combination with doxorubicin...
  18. ncbi request reprint Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials
    Dominik P Modest
    Department of Medicine III, University Hospital Grosshadern, University of Munich, Munich, Germany
    Oncology 83:241-7. 2012
    ..This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC)...
  19. doi request reprint Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy
    Michael Haas
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377 Munich, Germany
    J Cancer Res Clin Oncol 139:681-9. 2013
    ..CA 19-9 is the only established tumor marker in pancreatic cancer (PC); the prognostic role of other serum markers like CEA, CRP, LDH or bilirubin has not yet been defined...
  20. doi request reprint Erlotinib 150 mg daily plus chemotherapy in advanced pancreatic cancer: an interim safety analysis of a multicenter, randomized, cross-over phase III trial of the 'Arbeitsgemeinschaft Internistische Onkologie'
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Anticancer Drugs 21:94-100. 2010
    ..12%), and hand-foot syndrome (7 vs. 0%). No treatment-related death was observed. In conclusion, this interim safety analysis suggests that treatment with erlotinib 150 mg/day is feasible in combination with capecitabine or gemcitabine...
  21. doi request reprint Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
    Volker Heinemann
    Department of Hematology Oncology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchionini Street 15, 81377 Munich, Germany
    Cancer Treat Rev 35:262-71. 2009
    ..While molecular parameters help to predict treatment efficacy upfront, skin toxicity has been accepted as an independent predictor of response during exposure to anti-EGFR therapy...
  22. doi request reprint Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
    Clin Colorectal Cancer 10:317-24. 2011
    ..7% and 5.0%. This analysis aimed to evaluate clinical and histopathologic factors associated with 60-day mortality in first-line therapy for metastatic colorectal cancer (mCRC)...
  23. ncbi request reprint Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer
    Ralf Wilkowski
    Clinic for Radiation Oncology, LMU University Hospital Grosshadern, Munich, Germany
    JOP 7:349-60. 2006
    ..Gemcitabine and 5-fluorouracil (5-FU) sensitize tumor cells to radiation. Furthermore, 5-FU enhances the cytotoxic effect of gemcitabine...
  24. doi request reprint Outcome of patients with metastatic colorectal cancer depends on the primary tumor site (midgut vs. hindgut): analysis of the FIRE1-trial (FuFIRI or mIROX as first-line treatment)
    Dominik P Modest
    aDepartment of Medicine III, University Hospital Grosshadern bInstitute of Medical Informatics, Biometry and Epidemiology, University of Munich, Munich cKlinikum St Marien, Amberg dKlinikum Chemnitz, Chemnitz eOnkologische Praxis Landshut, Landshut fGerman Cancer Consortium DKTK gGerman Cancer Research Center DKFZ, Heidelberg, Germany
    Anticancer Drugs 25:212-8. 2014
    ..However, the effect appeared less pronounced in the mIROX arm. Further datasets from large trials with various regimens are required as confirmation. ..
  25. doi request reprint Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial
    Dominik P Modest
    Department of Medicine III and Comprehensive Cancer Center, University of Munich, Munich, Germany
    Acta Oncol 52:956-62. 2013
    ..Moreover, correlations of ETS with clinical characteristics and prognostic markers were evaluated...
  26. doi request reprint Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 77:40-8. 2009
    ..No data have previously been available regarding the current treatment of patients with pancreatic cancer (PC) in German hospitals and medical practices...
  27. ncbi request reprint Role of gemcitabine in the treatment of advanced and metastatic breast cancer
    Volker Heinemann
    Medical Clinic III, Klinikum Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Oncology 64:191-206. 2003
    ....
  28. doi request reprint Early tumor shrinkage in metastatic colorectal cancer: retrospective analysis from an irinotecan-based randomized first-line trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, Ludwig Maximilians University of Munich, Munich, Germany
    Cancer Sci 104:718-24. 2013
    ..Non-ETS is a heterogeneous subgroup where patients with minor shrinkage clearly benefit from treatment, and patients with early progression or development of new lesions have an unfavorable prognosis...
  29. doi request reprint Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group
    Nicolas Moosmann
    University of Munich, Klinikum Muenchen Grosshadern, Germany
    J Clin Oncol 29:1050-8. 2011
    ....
  30. doi request reprint Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Stu
    Sebastian Stintzing
    Department of Haematology and Oncology, Comprehensive Cancer Center, Klinikum Grosshadern, University of Munich, Munich, Germany
    Int J Cancer 132:236-45. 2013
    ..This effect of Cet-ST is independent of the KRAS mutation status, suggesting that Cet-ST rather relates to constitutional factors of the patient than alterations of the EGFR pathway in the tumour...
  31. ncbi request reprint Combined chemoradiotherapy for isolated local recurrence after primary resection of pancreatic cancer
    Ralf Wilkowski
    Clinic for Radiation Oncology, LMU University Hospital Grosshadern, Munich, Germany
    JOP 7:34-40. 2006
    ..Primary resectability is expected in up to 20% of pancreatic cancer patients. While most patients relapse with distant metastases, approximately 30% of patients show isolated local recurrence without evidence of distant metastases...
  32. doi request reprint KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377, Munich, Germany
    J Gastroenterol 48:544-8. 2013
    ..It has not yet been defined if KRAS has a prognostic value or is a predictive biomarker for the efficacy of erlotinib in advanced pancreatic cancer (PC)...
  33. doi request reprint Circulating immunogenic cell death biomarkers HMGB1 and RAGE in breast cancer patients during neoadjuvant chemotherapy
    Oliver J Stoetzer
    Haematology and Oncology Outpatient Cancer Care Center, Franz Schrank Str 2, 80638, Munich, Germany
    Tumour Biol 34:81-90. 2013
    ..053). Markers of immunogenic cell death are valuable for the diagnosis of MBC and early estimation of response to neoadjuvant therapy in LBC patients...
  34. doi request reprint 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer
    Alexander R Haug
    Department of Nuclear Medicine, Ludwig Maximilians University of Munich, Munich, Germany
    J Nucl Med 53:371-7. 2012
    ..The objective of the present study was to evaluate (18)F-FDG PET/CT for predicting survival in these patients...
  35. pmc A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...
  36. doi request reprint Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
    Dominik P Modest
    Medical Department III, Hospital of the University, University of Munich, Germany
    Anticancer Drugs 22:913-8. 2011
    ..Compared with KRAS codon 12 mutations, codon 13-mutated mCRC presents as a more aggressive disease frequently associated with local and distant metastases at first diagnosis...
  37. doi request reprint Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer
    Nicolas Moosmann
    University of Munich, Medical Department III, Klinikum Muenchen Grosshadern, Germany
    Clin Colorectal Cancer 7:110-7. 2008
    ....
  38. ncbi request reprint Chemoradiation for ductal pancreatic carcinoma: principles of combining chemotherapy with radiation, definition of target volume and radiation dose
    Ralf Wilkowski
    Clinic for Radiation Oncology, LMU University Hospital Grosshadern, Munich, Germany
    JOP 6:216-30. 2005
    ..Intensity-modulated radiotherapy has been developed to improve target-specific radiation and to reduce organ toxicity. Its clinical relevance still needs to be defined...
  39. ncbi request reprint Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials
    Volker Heinemann
    Department of Hematology Oncology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Semin Oncol 29:9-16. 2002
    ..Numerous ongoing randomized trials are presently investigating gemcitabine-based combination regimens involving such agents as cisplatin, oxaliplatin, irinotecan, docetaxel, 5-fluorouracil, capecitabine, or pemetrexed...
  40. doi request reprint Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy
    Christin Wittwer
    Institute of Clinical Chemistry, University Hospital Munich Grosshadern, Munich, Germany
    Int J Cancer 133:2619-30. 2013
    ..Thus, courses of circulating nucleosomes and immunogenic cell death markers HMGB1 and sRAGE show prognostic relevance in PC patients undergoing chemotherapy. ..
  41. ncbi request reprint Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC)
    Hans Joachim Stemmler
    Medical Department III, University Hospital of Munich, Grosshadern, Germany
    Onkologie 28:582-6. 2005
    ..The study specifically focussed on the influence of the continuation of trastuzumab-based treatment despite tumor progression on survival...
  42. doi request reprint Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, Ludwig Maximilian University of Munich, Munich, Germany
    Clin Cancer Res 19:225-35. 2013
    ....
  43. doi request reprint Cetuximab-based or bevacizumab-based first-line treatment in patients with KRAS p.G13D-mutated metastatic colorectal cancer: a pooled analysis
    Dominik Paul Modest
    Department of Medicine III, Klinikum Grosshadern, University of Munich, Munich, Germany
    Anticancer Drugs 23:666-73. 2012
    ..G13D mutant mCRC. The combination with capecitabine and irinotecan was associated with a more favourable outcome compared with infusional 5-FU and oxaliplatin...
  44. ncbi request reprint Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer
    Ralf Wilkowski
    Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern der LMU München, Marchioninistrasse 15, 81377, Munchen, Germany
    World J Surg 28:1011-8. 2004
    ..This preoperative treatment approach is highly effective and appears to improve survival in patients whose tumors are rendered completely resectable...
  45. doi request reprint UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?
    Christoph Schulz
    Department of Haematology, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
    Anticancer Drugs 20:867-79. 2009
    ....
  46. doi request reprint Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)
    Dorit Di Gioia
    Department of Internal Medicine III, Klinikum Grosshadern, University Hospital, Munich, Germany
    Tumour Biol 32:777-85. 2011
    ..Further improvements on their sensitivity can be probably achieved by a prospective study design and by combining with other biomarkers like CA-125 and HER2 shed antigen...
  47. ncbi request reprint Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer
    S Boeck
    Medizinische Klinik und Poliklinik III, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen, Germany
    Ann Oncol 19:340-7. 2008
    ..To compare the efficacy and safety of three different chemotherapy doublets in the treatment of advanced pancreatic cancer (PC)...
  48. doi request reprint Percutaneous radiofrequency ablation (RFA) or robotic radiosurgery (RRS) for salvage treatment of colorectal liver metastases
    Sebastian Stintzing
    Department of Medical Oncology and Comprehensive Cancer Center, Klinikum Grosshadern, LMU, Munich, Germany
    Acta Oncol 52:971-7. 2013
    ..In this analysis, two local therapies: 1) single session robotic radiosurgery (RRS) and 2) percutaneous radiofrequency ablation (RFA) were compared in a total of 60 heavily pretreated colorectal cancer patients...
  49. doi request reprint Intrathecal trastuzumab (Herceptin) and methotrexate for meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer: a case report
    Hans Joachim Stemmler
    Medical Department III, Ludwig Maximilians University of Munich, Klinikum Grosshadern, Munich, Germany
    Anticancer Drugs 19:832-6. 2008
    ..This case report gives details regarding the clinical course of a breast cancer patient who received intrathecal trastuzumab and methotrexate via lumbar puncture for meningeal carcinomatosis of HER2-overexpressing MBC...
  50. doi request reprint Combined resection of colorectal hepatic-pulmonary metastases shows improved outcome over chemotherapy alone
    Georgios Meimarakis
    Department of General Thoracic Surgery, University of Munich Grosshadern, Marchioninistrasse 15, Munich, Germany
    Langenbecks Arch Surg 398:265-76. 2013
    ..The objective of this retrospective study was to assess the survival of patients after resection of hepatic and pulmonary colorectal metastases to identify predictors of long-term survival...
  51. ncbi request reprint Glucose and lipid metabolism in patients with advanced pancreatic cancer receiving palliative chemotherapy
    Katharina Zeiss
    Department of Internal Medicine III and Comprehensive Cancer Center, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    Anticancer Res 33:287-92. 2013
    ..The role of diabetes mellitus (DM) in the pathogenesis of pancreatic cancer (PC) and its prognostic role on patients with advanced disease remain undefined...
  52. doi request reprint External validation of 2 prognostic indices for patients with advanced pancreatic cancer treated with first-line therapy
    Michael Haas
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Pancreas 41:738-44. 2012
    ..The objective of this study was to perform an external validation of 2 Asian prognostic indices for patients with advanced pancreatic cancer...
  53. pmc UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer
    Christoph Schulz
    Department of Haematology and Oncology, Ludwig Maximilians University of Munich, Campus Grosshadern, Marchioninistr 15, Munich 81377, Germany
    World J Gastroenterol 15:5058-66. 2009
    ....
  54. doi request reprint Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Ludwig Maximilians University of Munich, Munich, Germany
    Clin Cancer Res 16:986-94. 2010
    ..The clinical relevance of CA 19-9 as surrogate biomarker in advanced pancreatic cancer is a matter of debate...
  55. ncbi request reprint Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma
    Ralf Wilkowski
    Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Universitat Munchen, Munchen, Germany
    Int J Radiat Oncol Biol Phys 58:768-72. 2004
    ..To analyze, in a prospective clinical trial, the efficacy and toxicity of concurrent radiotherapy and chemotherapy with gemcitabine and cisplatin in patients with incompletely (R1) resected pancreatic cancer...
  56. ncbi request reprint Gemcitabine-based combination treatment of pancreatic cancer
    Volker Heinemann
    Klinikum Grosshadern, III Medical Clinic, Munich, Germany
    Semin Oncol 29:25-35. 2002
    ..Four-drug regimens indicate a possible improvement in treatment outcome. However, their application may be limited to selected patients with good performance status...
  57. ncbi request reprint [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective]
    Ralf Wilkowski
    Klinik und Poliklinik für Strahlentherapie und Radioonkologie, Klinikum Grosshadern, Ludwig Maximilians Universitat Munchen, Munich, Germany
    Strahlenther Onkol 179:78-86. 2003
    ..In the present paper our pilot data of concomitant and sequential chemoradiation with gemcitabine and cisplatin are presented...
  58. ncbi request reprint Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT
    Gerwin P Schmidt
    Institute of Clinical Radiology, University Hospitals Munich Grosshadern, Marchioninistr 15, 81377 Munich, Germany
    Eur J Radiol 65:47-58. 2008
    ..To compare the diagnostic accuracy for the detection of tumor recurrence in breast cancer patients using whole-body-MRI (WB-MRI) at 1.5 or 3T compared to FDG-PET-CT...
  59. doi request reprint Long-term follow-up of patients with metastatic breast cancer: results of a retrospective, single-center analysis from 2000 to 2005
    Sandra Geiger
    Medical Department III, Ludwig Maximilians University of Munich, Campus Grosshadern, Germany
    Anticancer Drugs 22:933-9. 2011
    ....
  60. ncbi request reprint Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Anticancer Drugs 18:1109-11. 2007
    ..Thus, pulmonary side effects should be regarded carefully in pancreatic cancer patients receiving palliative therapy with gemcitabine and erlotinib...
  61. doi request reprint Surgical treatment concepts for patients with pancreatic cancer in Germany--results from a national survey conducted among members of the "Chirurgische Arbeitsgemeinschaft Onkologie" (CAO) and the "Arbeitsgemeinschaft Internistische Onkologie" (AIO) of th
    Mirja Sargent
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilian University of Munich, Munich, Germany
    Langenbecks Arch Surg 396:223-9. 2011
    ..To date, only limited data are available regarding the routine surgical management of patients with exocrine pancreatic cancer (PC) in German community and university hospitals...
  62. ncbi request reprint Gemcitabine plus cisplatin for the treatment of metastatic breast cancer
    Volker Heinemann
    Klinikum Grosshadern, Munich, Germany
    Clin Breast Cancer 3:24-9. 2002
    ..The gemcitabine/ cisplatin combination, therefore, offers a tolerable and effective treatment option, particularly for patients whose disease progressed after treatment with anthracyclines and/or taxanes...
  63. ncbi request reprint Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy?
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany
    Onkologie 30:39-42. 2007
    ..CA 19-9 pretreatment levels as well as CA 19-9 kinetics during systemic chemotherapy can provide prognostic information regarding survival of patients with metastatic PC...
  64. doi request reprint Prospective multicenter randomized phase III study of weekly versus standard docetaxel (D2) for first-line treatment of metastatic breast cancer
    Hans Joachim Stemmler
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilian University of Munich, Munich, Germany
    Oncology 79:197-203. 2010
    ..The present trial was initiated to randomly compare the toxicity and efficacy of weekly docetaxel versus its standard 3-weekly application...
  65. doi request reprint The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer
    Stefan Boeck
    Ludwig Maximilians University of Munich, Department of Internal Medicine III, Klinikum Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Future Oncol 4:41-50. 2008
    ..However, results from large randomized Phase III trials are still lacking and therefore no evidence-based treatment recommendation can be given for patients with advanced pancreatic cancer after failure of first-line gemcitabine...
  66. ncbi request reprint Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients
    Dorit Laessig
    Department of Internal Medicine III, University Hospital, Munich, Germany
    Anticancer Res 27:1963-8. 2007
    ..The aim of this study analysis was to determine the correlation between elevation of CEA and/or CA 15-3 and disease progression of metastatic breast cancer...
  67. ncbi request reprint Present and future treatment of pancreatic cancer
    Volker Heinemann
    Department of Hematology Oncology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Semin Oncol 29:23-31. 2002
    ..However, none of these combinations has yet reached the level of an evidence-based standard treatment...
  68. ncbi request reprint Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia
    Nicolas Moosmann
    Medizinische Klinik III, Campus Grosshadern, Klinikum der Ludwig Maximilians Universität München, Germany
    Onkologie 30:509-12. 2007
    ..Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases...
  69. doi request reprint Adjuvant cisplatin-based chemotherapy for resected NSCLC: one size fits all?
    Sandra Geiger
    Medical Department III, Ludwig Maximilians University of Munich, Germany
    Anticancer Drugs 21:799-804. 2010
    ..This review will discuss the extent to which individualized adjuvant treatment can be provided...
  70. ncbi request reprint Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncology 70:255-64. 2006
    ..It still remains to be defined whether the CA 19-9 response is a more reliable method for evaluating treatment efficacy compared to conventional imaging...
  71. doi request reprint Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge
    Hans Joachim Stemmler
    Department of Haematology and Oncology, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Munich, Germany
    Oncologist 13:739-50. 2008
    ....
  72. ncbi request reprint High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer
    V Heinemann
    Department of Medicine III, Klinikum Grosshadern, University of Munich, Marchioninistr 15, 81377, Munich, Germany
    Cancer Chemother Pharmacol 57:640-6. 2006
    ..Gemcitabine and cisplatin demonstrated synergistic activity in vitro and provides a new mechanism of drug interaction...
  73. doi request reprint Resistance to EGF-R (erbB-1) and VEGF-R modulating agents
    Wolfram C M Dempke
    University of Munich, University Hospital of Grosshadern, Department of Hematology and Oncology, Industriestrasse 41, D 81245 Munich, Germany
    Eur J Cancer 45:1117-28. 2009
    ..Ongoing research efforts will likely continue to identify additional resistance mechanisms, and these findings will hopefully translate into effective therapies for different cancers...
  74. ncbi request reprint Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier
    Hans Joachim Stemmler
    Medical Department III, Ludwig Maximilians University of Munich, Clinic Grosshadern, Munich, Germany
    Anticancer Drugs 18:23-8. 2007
    ....
  75. ncbi request reprint Cetuximab in the treatment of metastatic colorectal cancer
    Nicolas Moosmann
    University of Munich, Medical Department III, Klinikum Muenchen Grosshadern, Marchioninistrasse 15, D 81377 Munich, Germany
    Expert Opin Biol Ther 7:243-56. 2007
    ..Promising results have already been obtained in a trial combining irinotecan, bevacizumab and cetuximab...
  76. pmc The treatment of colorectal carcinoma with monoclonal antibodies: the importance of KRAS mutation analysis and EGFR status
    Sebastian Stintzing
    Medizinische Klinik und Poliklinik III, Klinikum der LMU München, Munchen, Germany
    Dtsch Arztebl Int 106:202-6. 2009
    ..Mutations in the KRAS gene can be demonstrated by the methods of molecular pathology and are a very important factor in the selection of molecular biological treatment options targeted against EGFR...
  77. doi request reprint Clinical relevance of circulating nucleosomes in cancer
    Stefan Holdenrieder
    Institute of Clinical Chemistry, University Hospital of Munich, Munich, Germany
    Ann N Y Acad Sci 1137:180-9. 2008
    ..Despite their non-tumor-specificity, kinetics of nucleosomes are valuable markers for the early estimation of therapeutic efficacy and may be helpful to adapting early cancer therapy in the future...
  78. ncbi request reprint Re-evaluation of HER2 status in metastatic breast cancer and tumor-marker guided therapy with vinorelbine and trastuzumab
    Hans Joachim Stemmler
    Medizinische Klinik III, Hämatologie Onkologie, Institut fur Klinische Chemie, LMU Munchen, Klinikum Grosshadern, Germany
    Onkologie 28:95-7. 2005
    ..In general, HER2 status in a primary lesion predicts the status of metastases, so that biopsy of metastatic lesions appears unnecessary...
  79. ncbi request reprint Importance of performance status for treatment outcome in advanced pancreatic cancer
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University of Munich, Marchioninistrasse 15, Munich 81377, Germany
    World J Gastroenterol 13:224-7. 2007
    ..By contrast, patients with a poor performance status (KPS < or = 80%) have no advantage from intensified therapy and should rather receive single-agent treatment...
  80. ncbi request reprint The role of adjuvant chemotherapy for patients with resected pancreatic cancer: systematic review of randomized controlled trials and meta-analysis
    Stefan Boeck
    Department of Internal Medicine III, Klinikum Grosshadern, Munich, Germany
    Oncology 72:314-21. 2007
    ..The role of adjuvant treatment strategies (including chemotherapy and chemoradiotherapy) following resection of pancreatic cancer remains controversial...
  81. doi request reprint Anticancer therapy induced cardiotoxicity: review of the literature
    Sandra Geiger
    Medical Department III, Haematology and Oncology, Ludwig Maximilians University of Munich, Campus Grosshadern, Munich, Germany
    Anticancer Drugs 21:578-90. 2010
    ..The diagnostic work-up, the cardiotoxic risk of anthracyclines and trastuzumab, and additionally, cardiotoxicity as a risk factor of a multimodal therapeutic approach in breast cancer patients is discussed in this study...
  82. ncbi request reprint Gemcitabine in metastatic breast cancer
    Volker Heinemann
    Medical Clinic III, Klinikum Grosshadern, Marchioninistrasse 15, 81377, Munich, Germany
    Expert Rev Anticancer Ther 5:429-43. 2005
    ....
  83. ncbi request reprint High efficacy and low toxicity of weekly docetaxel given as first-line treatment for metastatic breast cancer
    J Stemmler
    Medical Department III, University of Munich, DE 81377 Munich, Germany
    Oncology 68:71-8. 2005
    ..This phase II multicenter study prospectively analyzed the efficacy and toxicity of docetaxel given on a weekly schedule as first-line treatment of metastatic breast cancer...
  84. ncbi request reprint Apoptosis-related biomarkers sFAS, MIF, ICAM-1 and PAI-1 in serum of breast cancer patients undergoing neoadjuvant chemotherapy
    Debora M I Fersching
    Institute of Clinical Chemistry, University Hospital Munich, Munich, Germany
    Anticancer Res 32:2047-58. 2012
    ..Neoadjuvant chemotherapy improves surgical options and prognosis in patients with operable breast cancer. Predictive biomarkers are needed to choose the most effective therapy and to avoid unnecessary toxicity...
  85. doi request reprint 18F-FDG PET independently predicts survival in patients with cholangiocellular carcinoma treated with 90Y microspheres
    Alexander R Haug
    Department of Nuclear Medicine, Ludwig Maximilians University, Munich, Germany
    Eur J Nucl Med Mol Imaging 38:1037-45. 2011
    ..We aimed to evaluate the prognostic power of FDG PET/CT and that of pretherapeutic scintigraphy with (99m)Tc-labelled macroagglutinated albumin (MAA), an index of tumour vascularization...
  86. ncbi request reprint [Importance of neoadjuvant chemotherapy in gastrointestinal tumors. A new standard?]
    Nicolas Moosmann
    Medizinische Klinik III, Universitätsklinikum München Grosshadern, Marchioninistrasse 15, 81377 Munchen
    Med Klin (Munich) 102:551-62; quiz 563-4. 2007
  87. ncbi request reprint F-18-fluoro-2-deoxyglucose positron emission tomography/computed tomography in the follow-up of breast cancer with elevated levels of tumor markers
    Alexander Robert Haug
    Department of Nuclear Medicine, Ludwig Maximilians University of Munich, Germany
    J Comput Assist Tomogr 31:629-34. 2007
    ..The value of combined positron emission tomography (PET)/computed tomography (CT) in the follow-up of patients with breast cancer with elevated tumor markers but without proven metastases or local recurrence was assessed...
  88. doi request reprint Risk factors for surgical complications in distal pancreatectomy
    Hendrik Seeliger
    Department of Surgery, Munich University Medical Center, Germany
    Am J Surg 200:311-7. 2010
    ..Pancreatic fistula (PF) represents a major complication after distal pancreatectomy. In a consecutive series of 110 patients, risk factors for the incidence of PF and surgical morbidity were identified...
  89. doi request reprint Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer
    Nicolas Moosmann
    Medizinische Klinik III, Klinikum Muenchen Grosshadern, Marchioninistrasse 15, D 81377 Munchen, Germany
    Expert Rev Anticancer Ther 8:319-29. 2008
    ..This review presents recent data on oxaliplatin, cetuximab and the combination of both for mCRC as well as possible future indications in the palliative, adjuvant and neoadjuvant setting of modern CRC treatment...
  90. ncbi request reprint Gemcitabine: progress in the treatment of pancreatic cancer
    V Heinemann
    Klinikum Grosshadern, III Medical Clinic, Munich, Germany
    Oncology 60:8-18. 2001
    ..Inclusion of pancreatic cancer patients into clinical trials should be a major goal. Outside clinical trials, patients should present with an adequate PS (Karnofsky-performance index greater than or = 70) to qualify for chemotherapy...
  91. ncbi request reprint Capecitabine as second-line treatment for metastatic cholangiocarcinoma: a report of two cases
    J Stemmler
    Abteilung für Innere Medizin III, Universitätsklinik München, Germany
    Onkologie 25:182-4. 2002
    ..When advanced or metastatic disease is diagnosed, the therapeutic efforts are essentially directed toward palliation...
  92. ncbi request reprint Application of intrathecal trastuzumab (Herceptintrade mark) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer
    H J Stemmler
    Department of Internal Medicine III, Ludwig Maximilians University of Munich, Klinikum Grosshadern, D 81377 Munich, Germany
    Oncol Rep 15:1373-7. 2006
    ....
  93. ncbi request reprint High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study
    H J Stemmler
    Department of Medicine III, Klinikum Grosshadern, University of Munich, Germany
    Clin Oncol (R Coll Radiol) 17:630-5. 2005
    ..This multicentre phase II study aimed to evaluate the efficacy and tolerability of gemcitabine and cisplatin plus trastuzumab in previously treated patients with metastatic breast cancer (MBC)...
  94. ncbi request reprint Lasting remission following multimodal treatment in a patient with metastatic breast cancer
    H J Stemmler
    Department of Hematology Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany
    Anticancer Drugs 16:1135-7. 2005
    ..Further investigation of this approach is indicated in a subgroup of patients with oligometastatic breast cancer...
  95. ncbi request reprint Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study
    H J Stemmler
    Department of Hematology Oncology, University of Munich, Germany
    Anticancer Res 25:3047-54. 2005
    ....
  96. ncbi request reprint Gastrointestinal toxicity associated with weekly docetaxel treatment
    H J Stemmler
    Department of Internal Medicine III, Klinikum Grosshadern, University of Munich, Germany
    Ann Oncol 13:978-81. 2002
    ..These symptoms should alert the physician and supportive care management should be started aggressively and immediately...
  97. ncbi request reprint Characteristics of patients with brain metastases receiving trastuzumab for HER2 overexpressing metastatic breast cancer
    H J Stemmler
    Medical Department III, University of Munich, Grosshadern, Germany
    Breast 15:219-25. 2006
    ..Since one third of HER2 overexpressing patients with MBC developed BM despite effective trastuzumab treatment, new treatment strategies and closer surveillance may be warranted for these patients...
  98. ncbi request reprint Leukapheresis in chronic myelomonocytic leukemia with leukostasis syndrome: elevated serum lactate levels as an early sign of microcirculation failure
    J Stemmler
    Medizinische Klinik III, Abtl Hämatologie Onkologie, LMU Munchen, Klinikum Grosshadern, University of Munich, Germany
    Leuk Lymphoma 43:1427-30. 2002
    ..In our opinion, patients presenting with asymptomatic hyperleukocytosis may benefit from early leukapheresis, particularly when increasing serum lactate levels indicate the early onset of microcirculatory failure...
  99. ncbi request reprint [Risk and benefits of hormone replacement therapy by postmenopausal women. WHI-Study]
    V Heinemann
    Medizinische Klinik II, Grosshadern, Klinikum der Ludwig Maximilians Universität München
    Internist (Berl) 44:896-8. 2003
  100. ncbi request reprint [Tumor markers--how they should be applied]
    P Stieber
    Institut fur Klinische Chemie, Klinikum der Universitat Munchen Grosshadern
    MMW Fortschr Med 147:35, 37-9. 2005
    ..However, in order to ensue correct interpretation it is important to use the same test system...
  101. ncbi request reprint An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine
    U Jehn
    Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Leukemia 18:1476-81. 2004
    ..Responses are durable and long-lasting. Pts who relapsed following treatment with 2-CdA responded to subsequent retreatment with 2-CdA...